|
1.
|
Original article
|
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
|
|
2.
|
Original article
|
Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
|
|
3.
|
Other
|
Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. 2026/05
|
|
4.
|
Other
|
Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
|
|
5.
|
Other
|
Impact of prolonged warm ischemia during clamped partial nephrectomy: Comparison between Japanese and american cohorts. 2026/05
|
|
6.
|
Other
|
Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
|
|
7.
|
Other
|
Prognostic impact of early C-reactive proteindynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. 2026/05
|
|
8.
|
Case report
|
Requiring caution in the interpretation of donor- derived cell- free DNA levels during cancer treatment in a kidney
transplant recipient.: A case report 2026/05
|
|
9.
|
Other
|
Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
|
|
10.
|
Other
|
Who truly needs adjuvant therapy? A simple clinicopathologic model identifying real candidates for keynote-564-defined intermediate-high-risk clear cell renal cell carcinoma. 2026/05
|
|
11.
|
Original article
|
Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
|
|
12.
|
Original article
|
Feasibility and strategic endoscopic management of de novo kidney allograft stones: a retrospective study. 2026/04
|
|
13.
|
Original article
|
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
|
|
14.
|
Original article
|
Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations. 2026/03
|
|
15.
|
Case report
|
Safety management of kidneytransplantation in patients with Behçet’s disease: A case report with literature review 2026/02/10
|
|
16.
|
Case report
|
Anti-melanoma differentiation-associated Gene 5 antibody-positive interstitial lung disease, Induced by enfortumab vedotin plus pembrolizumab for Advanced urothelial carcinoma. 2026/02/05
|
|
17.
|
Original article
|
Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
|
|
18.
|
Original article
|
Risk assessment of cytomegalovirus reactivation after kidney transplantation under a universal preemptive strategy in the era of intravenous immunoglobulin-based desensitization therapy. 2026/02
|
|
19.
|
Original article
|
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
|
|
20.
|
Original article
|
Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
|
|
21.
|
Original article
|
Impact of prolonged warm ischemia during clamped partial nephrectomy: Comparison between Japanese and American cohorts. 2025/12
|
|
22.
|
Original article
|
Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
|
|
23.
|
Original article
|
Diagnostic agreement and limitations of the Banff automated system in kidney transplant biopsies. 2025/11/20
|
|
24.
|
Original article
|
Renal parenchymal defects occasionally observed in non–well-differentiated perirenal liposarcomas unlike in well-differentiated types. 2025/11
|
|
25.
|
Original article
|
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
|
|
26.
|
Original article
|
Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma. 2025/10
|
|
27.
|
Case report
|
Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: Case report 2025/09/01
|
|
28.
|
Original article
|
Extended follow-up of robot-assisted partial nephrectomy for renal hilar tumor: A prospective multi-institutional study. 2025/09
|
|
29.
|
Original article
|
Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
|
|
30.
|
Original article
|
Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
|
|
31.
|
Original article
|
Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
|
|
32.
|
Case report
|
Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases. 2025/08
|
|
33.
|
Other
|
Differential gene expression in endothelial cells highlights HLA-F as a marker for ABMR. 2025/08
|
|
34.
|
Original article
|
Donor-derived nephritis on pretransplant biopsy does not impair posttransplant renal function in recipients or donors. 2025/08
|
|
35.
|
Original article
|
Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
|
|
36.
|
Other
|
Incidence and causes of surgical reintervention following living kidney transplantation: Insights from 534 consecutive cases. 2025/08
|
|
37.
|
Original article
|
Long-term outcomes of cross-match positive living kidney transplantation: A retrospective study. 2025/08
|
|
38.
|
Original article
|
Optimization of a model for predicting renal function after living kidney transplantation using computed tomography volumetry. 2025/08
|
|
39.
|
Other
|
Performance of donor-derived cell-Free DNA testing for rejection detection in Japanese kidney transplants: Insights from a multicenter study. 2025/08
|
|
40.
|
Other
|
Relative changes in donor-derived cell-free DNA as a marker of allograft rejection in a kidney transplant recipient with metastatic cancer undergoing immunotherapy 2025/08
|
|
41.
|
Other
|
Surgical complications and risk factors in 2,095 cases of pure retroperitoneoscopic living donor nephrectomy: A 20-year experience. 2025/08
|
|
42.
|
Other
|
The coeffi cient of variation of tacrolimus QD at 1 year posttransplant is associated with mid-long term kidney graft function. 2025/08
|
|
43.
|
Original article
|
Personalized prediction model generated with machine learning for kidney function one year after living kidney donation. 2025/07/01
|
|
44.
|
Original article
|
Donor-derived cell-free DNA for diagnosing subclinical rejection: A pilot multicenter study in Japanese living-donor kidney transplantation. 2025/07
|
|
45.
|
Case report
|
Perioperative management of kidney transplantation in patients with myasthenia gravis: a case report with literature review. 2025/06/20
|
|
46.
|
Original article
|
Mini review Banff 2022 updated classification of renal allograft pathology. 2025/06/07
|
|
47.
|
Original article
|
Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
|
|
48.
|
Other
|
Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
|
|
49.
|
Other
|
Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
|
|
50.
|
Other
|
Gene profile of old donor kidney related to kidney function before and after kidney transplantation. 2025/05
|
|
51.
|
Other
|
Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
|
|
52.
|
Other
|
Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
|
|
53.
|
Original article
|
Outcomes of kidney transplants from elderly living donors: A retrospective cohort study in Japan. 2025/05
|
|
54.
|
Case report
|
Subacute thyroiditis during anti-programmed cell death protein 1 antibody therapy: A case report 2025/05
|
|
55.
|
Other
|
Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. 2025/05
|
|
56.
|
Original article
|
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. 2025/04
|
|
57.
|
Original article
|
Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
|
|
58.
|
Original article
|
Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
|
|
59.
|
Original article
|
Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study. 2025/03
|
|
60.
|
Original article
|
Outcomes of kidney transplantation in recipients with SARS-cov-2 infection: a 282-case single-center experience in Japan. 2025/02
|
|
61.
|
Original article
|
Release of apoptosis inhibitor of macrophage (AIM) from pentameric IgM in serum predicts prognosis after hemodialysis initiation. 2025/01/11
|
|
62.
|
Original article
|
Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
|
|
63.
|
Original article
|
Editorial comment on "Herpes zoster development in living kidney transplant recipients receiving low-dose rituximab" 2025/01
|
|
64.
|
Original article
|
Unveiling spatial immune cell profile in kidney allograft rejections using 36-plex immunofluorescence imaging. 2024/12
|
|
65.
|
Original article
|
Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era
to the immuno‑oncology era. 2024/11
|
|
66.
|
Case report
|
Partial bladder transplantation with en bloc kidney transplant-long-term, 17 years, the outcome of a "bladder patch technique" 2024/11
|
|
67.
|
Original article
|
Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
|
|
68.
|
Original article
|
Impact of tumor dissecting technique on trifecta achievement in patients requiring extended warm ischemia during robot-assisted partial nephrectomy. 2024/10/18
|
|
69.
|
Case report
|
Tips for percutaneous nephrolithotomy for transplant kidney stone. 2024/10/13
|
|
70.
|
Original article
|
Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study. 2024/10/03
|
|
71.
|
Original article
|
Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
|
|
72.
|
Original article
|
Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study. 2024/10
|
|
73.
|
Case report
|
Effectiveness of robot-assisted adrenalectomy for a giant adrenal hemangioma: A case report. 2024/09
|
|
74.
|
Original article
|
Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
|
|
75.
|
Original article
|
Renal outcome of living kidney donors aged more than 70 years. 2024/09
|
|
76.
|
Other
|
Reply to: Sebastiano Buti and Giulia Claire Giudice’s letter to the editor Re: Comparing a part to the whole—beware
of the disparity of the renal cell carcinoma prognostic models. 2024/09
|
|
77.
|
Original article
|
Comparison of surgical outcomes of robot‑assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single‑layer and double‑layer renorrhaphy. 2024/07/27
|
|
78.
|
Original article
|
Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
|
|
79.
|
Original article
|
Editorial comment on "Initial outcomes and surgical techniques of prostatic urethral lift for benign prostatic hyperplasia in Japan" 2024/07
|
|
80.
|
Original article
|
Robot-assisted partial nephrectomy with selective artery clamping for renal cell carcinoma in horseshoe kidney. 2024/07
|
|
81.
|
Original article
|
Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
|
|
82.
|
Case report
|
Treatment of allograft’ ureteral stones with percutaneous laser lithotripsy in a patient post-kidney-transplant: A case report. 2024/07
|
|
83.
|
Original article
|
Variations of vascular reconstruction in kidney transplantation with multiple renal graft arteries . 2024/06/11
|
|
84.
|
Other
|
Prediction of 10-yr Renal Graft Survival of Deceased Donors Based
on Preoperative Data Using Machine Learning 2024/06
|
|
85.
|
Original article
|
Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
|
|
86.
|
Other
|
ASO author refections: Recurrence risk prediction in high‑risk renal cell carcinoma: Where We Stand. 2024/05
|
|
87.
|
Original article
|
Editorial comment on prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. 2024/05
|
|
88.
|
Original article
|
Editorial comment on real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. 2024/05
|
|
89.
|
Original article
|
Editorial comment to The DDD score outperforms the RENAL score in predicting high-grade renal cell carcinoma. 2024/05
|
|
90.
|
Original article
|
Predicting recurrence after radical surgery for high‑risk renal cell carcinoma: Development and internal validation
of the “TOWARDS” score. 2024/05
|
|
91.
|
Original article
|
Comparison of estimated blood loss during living kidney transplantation according to the number of double-filtration plasmapheresis. 2024/04/14
|
|
92.
|
Original article
|
Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma:
Final prespecified overall survival analysis of CLEAR, a phase III study. 2024/04/10
|
|
93.
|
Original article
|
Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
|
|
94.
|
Original article
|
First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint
inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
|
|
95.
|
Original article
|
Safety of docetaxel in a patient with metastatic castration-resistant prostate cancer after kidney transplantation: A case report. 2024/04
|
|
96.
|
Original article
|
Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
|
|
97.
|
Original article
|
The medical cost and outcome of desensitization protocol in kidney transplantation recipients with high immunological risks. 2024/04
|
|
98.
|
Case report
|
Advanced renal cell carcinoma with Inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. 2024/03
|
|
99.
|
Original article
|
Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
|
|
100.
|
Original article
|
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the
lenvatinib-plus-pembrolizumab and sunitinib arms. 2024/03
|
|
101.
|
Original article
|
Prognostic value of the lung immune prognostic index on recurrence after radical surgery for high-risk renal
cell carcinoma. 2024/02/14
|
|
102.
|
Original article
|
Higher donor age and severe microvascular inflammation are risk factors for chronic rejection after treatment of active antibody-mediated rejection. 2024/02
|
|
103.
|
Original article
|
Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
|
|
104.
|
Original article
|
Metabolic and epigenetic reprogramming in a case of nuclear protein in testis (NUT) carcinoma of the retroperitoneum. 2024/01/23
|
|
105.
|
Original article
|
Clinical course of candidate renal tansplant recipients diagnosed with prostate cancer during pre-transplant screening test. 2024/01
|
|
106.
|
Original article
|
Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
|
|
107.
|
Original article
|
En bloc kidney transplantation from pediatric donors to teenage recipients: Two case reports. 2023/12/27
|
|
108.
|
Original article
|
A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection. 2023/12
|
|
109.
|
Original article
|
Clinicopathological analyses of chronic renal allograft arteriopathy after kidney transplantation. 2023/11
|
|
110.
|
Original article
|
A single-center retrospective comparative analysis of urinary continence in robotic prostatectomy with a combination of umbilical ligament preservation and Hood technique. 2023/10
|
|
111.
|
Original article
|
Effects of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. 2023/10
|
|
112.
|
Original article
|
Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
|
|
113.
|
Original article
|
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. 2023/09/15
|
|
114.
|
Case report
|
A case of kidney transplantation for complete C4 deficiency with recurrent IgM-monoclonal gammopathy of renal significance (MGRS) associated nephropathy. 2023/09
|
|
115.
|
Original article
|
Editorial Comment to Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. 2023/09
|
|
116.
|
Original article
|
Machine learning-based prediction of postoperative mortality in emergency colorectal surgery: A retrospective, multicenter cohort study using Tokushukai medical database. 2023/09
|
|
117.
|
Other
|
Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. 2023/09
|
|
118.
|
Original article
|
Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated
with pembrolizumab. 2023/07
|
|
119.
|
Original article
|
Comparison of three prognostic and predictive scores in 10 patients with COVID-19 pneumonia caused by nosocomial infection. 2023/07
|
|
120.
|
Original article
|
Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
|
|
121.
|
Review article
|
Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
|
|
122.
|
Original article
|
Kidney transplantation after multiple urinary tract conversion with an ileal conduit: A case report. 2023/05/14
|
|
123.
|
Original article
|
Pregnancy complications and impact on kidney allograft after kidney transplantation in IgA nephropathy. 2023/05/04
|
|
124.
|
Original article
|
Case report: suspected hyperacute rejection during living kidney transplantation. 2023/05/01
|
|
125.
|
Original article
|
Long-term prolonged-release tacrolimus outcomes in living donor kidney transplantation: The Japan academic consortium of kidney transplantation study-II. 2023/05
|
|
126.
|
Case report
|
Long-time survival of a renal transplant recipient with metastatic mucinous tubular and spindle cell carcinoma: A case report. 2023/05
|
|
127.
|
Original article
|
Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
|
|
128.
|
Original article
|
Editorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. 2023/03
|
|
129.
|
Original article
|
Efficacy of combined pembrolizumab and pelvic radiotherapy for bladder cancer with rectal metastases. 2023/03
|
|
130.
|
Original article
|
Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. 2023/03
|
|
131.
|
Original article
|
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. 2023/03
|
|
132.
|
Original article
|
Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
|
|
133.
|
Original article
|
Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
|
|
134.
|
Original article
|
Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
|
|
135.
|
Original article
|
A Comparative Study on the Variation in Seropositivity Rates After 2-Dose COVID-19 Vaccination Before or After Transplant: A Single-Center Analysis. 2022/12
|
|
136.
|
Original article
|
Analyses of operative time according to procedure phases during robot-assisted laparoscopic partial nephrectomy using the iPhone application “My Intuitives” 2022/11
|
|
137.
|
Original article
|
Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
|
|
138.
|
Original article
|
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
|
|
139.
|
Case report
|
Allogeneic kidney transplantation after COVID-19: A case report. 2022/07
|
|
140.
|
Case report
|
Case report of COVID-19 infection after kidney transplantation treated with casirivimab-imdevimab and mycophenolate mofetil changed to everolimus. 2022/07
|
|
141.
|
Case report
|
Suspected pneumonia caused by coronavirus disease 2019 after kidney transplantation: A case report. 2022/07
|
|
142.
|
Original article
|
New longitudinal component of the RENAL nephrometry score for predicting the operative complexity in transperitoneal robot-assisted partial nephrectomy. 2022/06
|
|
143.
|
Original article
|
Surgical outcomes of robot-assisted laparoscopic partial nephrectomy for cystic renal cell carcinoma. 2022/06
|
|
144.
|
Original article
|
Treatment with bortezomib for recurrent proliferative glomerulonephritis with monoclonal IgG deposits in kidney allograft. Case report and review of the literature. 2022/05/06
|
|
145.
|
Original article
|
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A retrospective cohort study at a single transplant institute in Japan. 2022/05
|
|
146.
|
Original article
|
Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
|
|
147.
|
Original article
|
Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
|
|
148.
|
Original article
|
Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
|
|
149.
|
Case report
|
Two laparotomy surgeries to achieve hemostasis after kidney transplantation in a patient with frailty: a case report. 2022/01
|
|
150.
|
Case report
|
A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. 2021/12/30
|
|
151.
|
Original article
|
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
|
|
152.
|
Original article
|
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
|
|
153.
|
Original article
|
Comparison of surgical outcomes between enucleation and standard resection in robot-assisted partial nephrectomy for completely endophytic renal tumors through a 1:1 propensity score-matched analysis. 2021/12
|
|
154.
|
Original article
|
Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
|
|
155.
|
Original article
|
Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. 2021/12
|
|
156.
|
Original article
|
Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2021/11
|
|
157.
|
Original article
|
Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma. 2021/11
|
|
158.
|
Original article
|
Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
|
|
159.
|
Original article
|
Greater renal function benefit from enucleation technique for more complex renal tumors in robot-assisted partial nephrectomy. 2021/10
|
|
160.
|
Original article
|
Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
|
|
161.
|
Original article
|
Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. 2021/10
|
|
162.
|
Original article
|
Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
|
|
163.
|
Original article
|
Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
|
|
164.
|
Original article
|
Early dark cortical band sign on CT for differentiating clear cell renal cell carcinoma from fat poor angiomyolipoma and detecting peritumoral pseudocapsule. 2021/08
|
|
165.
|
Original article
|
Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
|
|
166.
|
Original article
|
Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
|
|
167.
|
Case report
|
Robot-assisted laparoscopic partial nephrectomy for allograft renal cell carcinoma: A case report. 2021/06
|
|
168.
|
Original article
|
Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
|
|
169.
|
Original article
|
Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
|
|
170.
|
Original article
|
Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
|
|
171.
|
Original article
|
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. 2021/04
|
|
172.
|
Original article
|
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
|
|
173.
|
Original article
|
Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. 2021/04
|
|
174.
|
Original article
|
Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
|
|
175.
|
Original article
|
Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
|
|
176.
|
Original article
|
The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
|
|
177.
|
Original article
|
Comparison of postoperative recovery after robot-assisted partialnephrectomy of T1 renal tumors through retroperitoneal ortransperitoneal approach: A Japanese single institutional analysis. 2021/02
|
|
178.
|
Original article
|
Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. 2021/02
|
|
179.
|
Original article
|
Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot‑assisted partial nephrectomy using enhanced MDCT. 2021/01
|
|
180.
|
Other
|
Editorial comment to successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone. 2021/01
|
|
181.
|
Original article
|
Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
|
|
182.
|
Original article
|
Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
|
|
183.
|
Original article
|
Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study. 2020/11
|
|
184.
|
Original article
|
Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
|
|
185.
|
Case report
|
Total nephroureterocystectomy and urethrectomy due to urothelial carcinoma associated with the BK polyomavirus
infection after kidney transplantation: a case report with literature review. 2020/11
|
|
186.
|
Original article
|
Mid-term outcome of transarterial embolization of renal artery pseudoaneurysm and arteriovenous fistula after partial nephrectomy screened by early postoperative contrast-enhanced CT. 2020/09
|
|
187.
|
Original article
|
Outcomes of minimally invasive partial nephrectomy among very elderly patients: report from the RESURGE collaborative international database. 2020/09
|
|
188.
|
Original article
|
Trifecta outcomes of partial nephrectomy in patients over 75 years old: Analysis of the renal surgery in elderly (resurge) group. 2020/09
|
|
189.
|
Original article
|
Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
|
|
190.
|
Original article
|
Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
|
|
191.
|
Original article
|
Editorial comment to validation of a kidney model made of N-composite gel as a training tool for laparoscopic partial nephrectomy. 2020/06
|
|
192.
|
Original article
|
The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
|
|
193.
|
Original article
|
Editorial comment to postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome. 2020/05
|
|
194.
|
Original article
|
Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
|
|
195.
|
Original article
|
Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
|
|
196.
|
Original article
|
Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
|
|
197.
|
Original article
|
Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
|
|
198.
|
Original article
|
Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
|
|
199.
|
Original article
|
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. 2020/03
|
|
200.
|
Original article
|
Image quality of early postoperative CT angiography with reduced contrast material and radiation dose using model-based iterative reconstruction for screening of renal pseudoaneurysms after partial nephrectomy. 2020/03
|
|
201.
|
Original article
|
Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. 2020/01
|
|
202.
|
Original article
|
Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). 2020/01
|
|
203.
|
Original article
|
Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients. 2019/11
|
|
204.
|
Original article
|
Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. 2019/11
|
|
205.
|
Original article
|
Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions. 2019/08
|
|
206.
|
Original article
|
Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
|
|
207.
|
Original article
|
RBM10 - TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart florescence in-situ hybridisation: study of 10 cases and a literature review. 2019/08
|
|
208.
|
Original article
|
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. 2019/08
|
|
209.
|
Original article
|
Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy carried out using the enucleation technique. 2019/07
|
|
210.
|
Original article
|
Outcomes of partial and radical nephrectomy in octogenarians − A multicenter international study.(Resurge) 2019/07
|
|
211.
|
Original article
|
Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
|
|
212.
|
Original article
|
Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
|
|
213.
|
Original article
|
Outcomes, complications, and economic impact of ABO-incompatible living kidney transplantation: A single‐center Japanese cohort study. 2019/06
|
|
214.
|
Original article
|
Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
|
|
215.
|
Original article
|
Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. 2019/04
|
|
216.
|
Original article
|
Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
|
|
217.
|
Original article
|
A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. 2019/03
|
|
218.
|
Original article
|
Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. 2019/02
|
|
219.
|
Other
|
Editorial comment from Dr Takagi to acute kidney injury and intermediate-term renal function after clampless partial nephrectomy. 2019/01
|
|
220.
|
Original article
|
Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. 2018/12
|
|
221.
|
Original article
|
Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible:A randomized trial. 2018/12
|
|
222.
|
Original article
|
Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. 2018/10
|
|
223.
|
Original article
|
Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
|
|
224.
|
Original article
|
Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. 2018/10
|
|
225.
|
Original article
|
Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. 2018/09
|
|
226.
|
Original article
|
Outcome of the risk-stratified desensitization protocol in donor-specific antibody-positive living kidney transplant recipients: a retrospective study. 2018/09
|
|
227.
|
Original article
|
Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
|
|
228.
|
Original article
|
Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
|
|
229.
|
Original article
|
Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. 2018/06
|
|
230.
|
Original article
|
Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
|
|
231.
|
Original article
|
Response to cao et al. re: Comparison of surgical outcomes between resection and enucleation in robot-assisted laparoscopic partial nephrectomy for renal tumors according to the surface-intermediate-base margin score: A propensity score-matched study. 2018/04
|
|
232.
|
Original article
|
Robot-assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity score-matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. 2018/04
|
|
233.
|
Original article
|
Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. 2017/12
|
|
234.
|
Original article
|
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2017/12
|
|
235.
|
Review article
|
Pathological Classification of Renal Cell Carcinoma, based on WHO2016 Classification 2017/12
|
|
236.
|
Original article
|
Impact of preoperative proteinuria on renal functional outcomes after open partial nephrectomy in patients with a solitary kidney. 2017/11
|
|
237.
|
Original article
|
Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. 2017/09
|
|
238.
|
Original article
|
Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. 2017/09
|
|
239.
|
Original article
|
Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. 2017/09
|
|
240.
|
Original article
|
Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. 2017/08
|
|
241.
|
Original article
|
Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. 2017/07
|
|
242.
|
Original article
|
Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. 2017/07
|
|
243.
|
Case report
|
A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy. 2017/05
|
|
244.
|
Original article
|
Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. 2017/03
|
|
245.
|
Original article
|
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. 2017/02
|
|
246.
|
Original article
|
Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. 2017/02
|
|
247.
|
Original article
|
Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-Metastatic Renal Cancer in Long-Term Dialysis Patients. 2017/02
|
|
248.
|
Original article
|
Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
|
|
249.
|
Original article
|
Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
|
|
250.
|
Original article
|
Editorial Comment to Practical ex-vivo evaluation of application of surgical clips to sutures during re-approximation of renal tissue in partial nephrectomy. 2016/11
|
|
251.
|
Original article
|
A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell
carcinoma: a retrospective non-randomized observational study of initial outcomes. 2016/10
|
|
252.
|
Original article
|
Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. 2016/10
|
|
253.
|
Original article
|
Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. 2016/09
|
|
254.
|
Original article
|
Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases. 2016/07
|
|
255.
|
Original article
|
Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. 2016/06
|
|
256.
|
Original article
|
The magnitude of best tumor shrinkage during second-line targeted therapy affects progressionfree survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/06
|
|
257.
|
Case report
|
Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients 2016/04/01
|
|
258.
|
Original article
|
Efficacy and feasibility of low-dose rate brachytherapy for prostate cancer in renal transplant recipients. 2016/04/01
|
|
259.
|
Original article
|
Robot-assisted radical prostatectomy for localized prostate cancer in asian renal transplant recipients. 2016/04
|
|
260.
|
Original article
|
The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/03
|
|
261.
|
Original article
|
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. 2016/02
|
|
262.
|
Original article
|
The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava 2016/02
|
|
263.
|
Original article
|
Functional recovery from extended warm ischemia associated with partial nephrectomy. 2016/01
|
|
264.
|
Original article
|
Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. 2015/12
|
|
265.
|
Original article
|
Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: Importance of the new baseline glomerular filtration rate. 2015/12
|
|
266.
|
Original article
|
Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. 2015/12
|
|
267.
|
Other
|
Possible impact of continuous drainage after minimally invasive partial nephrectomy. 2015/11
|
|
268.
|
Original article
|
Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. 2015/10
|
|
269.
|
Original article
|
A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. 2015/09
|
|
270.
|
Original article
|
Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for ≥T1b renal tumors. 2015/09
|
|
271.
|
Original article
|
Multicenter validation of surgeon assessment of renal preservation in comparison to measurement with 3D image analysis. 2015/09
|
|
272.
|
Case report
|
Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. 2015/08
|
|
273.
|
Case report
|
Combination of molecular targeted therapy and surgery for a patient with metastatic renal cell carcinoma with a poor prognosis. 2015/07
|
|
274.
|
Original article
|
Comparison of 2 computed tomography-based methods to estimate preoperative and postoperative renal parenchymal volume and correlation with functional changes after partial nephrectomy. 2015/07
|
|
275.
|
Review article
|
Analysis of atrophy after camped partial nephrectomy and potential impact of ischemia. 2015/06
|
|
276.
|
Original article
|
Decline in renal function after partial nephrectomy:Etiology and prevention. 2015/06
|
|
277.
|
Original article
|
Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. 2015/04
|
|
278.
|
Original article
|
Compensatory hypertrophy after partial and radical nephrectomy in adults. 2014/12
|
|
279.
|
Original article
|
Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. 2014/12
|
|
280.
|
Original article
|
Assessment of outcomes in partial nephrectomy incorporating detailed functional analysis. 2014/11
|
|
281.
|
Original article
|
Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease. 2014/11
|
|
282.
|
Original article
|
Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. 2014/10
|
|
283.
|
Original article
|
Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. 2014/09
|
|
284.
|
Original article
|
Poorly functioning kidneys recover from ischemia after partial nephrectomy as well as strongly functioning kidneys. 2014/09
|
|
285.
|
Original article
|
Cytoreductive nephrectomy for metastatic renal cell carcinoma:A population-based analysis of perioperative outcomes according to clinical stage. 2014/08
|
|
286.
|
Original article
|
Predictors of precision of excision and reconstruction in partial nephrectomy. 2014/07
|
|
287.
|
Original article
|
Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. 2014/06
|
|
288.
|
Original article
|
Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. 2014/05
|
|
289.
|
Original article
|
Stage migration of renal cell carcinoma at a single Japanese university hospital: 24-year study. 2014/04
|
|
290.
|
Original article
|
Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of
4-Weeks-on and 2-Weeks-off 2014/03
|
|
291.
|
Original article
|
Mannitol has no impact on renal function after open partial nephrectomy in solitary kidneys 2014/02
|
|
292.
|
Original article
|
The influence of RENAL nephrometry score on pre-ruptured pseudoaneurysm formation detected by computed tomography angiography in early postoperative period after minimally invasive partial nephrectomy. 2014/01
|
|
293.
|
Original article
|
Predictors of precision of excision and reconstruction in partial nephrectomy 2013/12
|
|
294.
|
Original article
|
The utility of monitoring serum KL-6 level for predicting the onset of mTOR inhibitors induced interstitial lung disease 2013/07
|
|
295.
|
Original article
|
Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to Treatment Era Including Cytokine and Targeted Therapy 2013/04
|
|
296.
|
Original article
|
Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience 2013
|
|
297.
|
Original article
|
Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma 2012/11
|
|
298.
|
Original article
|
Cytoreductive nephrectomy for pT3b-T4 M1 renal cell carcinoma in 39 patients: single center analysis 2012/09
|
|
299.
|
Original article
|
Predictors for postoperative renal function after open partial nephrectomy: Including postoperative biomarkers 2012/09
|
|
300.
|
Original article
|
Impact of the tumor enhancement pattern in computed tomography for the differential diagnosis of renal cell carcinoma and benign renal tumor 2011/12
|
|
301.
|
Original article
|
Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancer-specific survival 2011/12
|
|
302.
|
Original article
|
Decompressive surgery in combination with preoperative transcatheter arterial embolization: Successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression 2011/10
|
|
303.
|
Original article
|
Analysis of laparoscopic radical nephrectomy for renal cell carcinoma patients with end stage kidney disease requiring hemodialysis 2011/09
|
|
304.
|
Original article
|
Postoperative renal function after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease: a comparison with radical nephrectomy 2011/06
|
|
305.
|
Original article
|
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center 2011/05
|
|
306.
|
Original article
|
Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. 2010
|
|
307.
|
Original article
|
Evaluation of Low-Dose Rituximab Induction Therapy in Living Related Kidney Transplantation. 2010
|
|
Display 5 items
|
|
Display all(307)
|
